Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells

Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats

(2021) Krit Jaikumkao et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells

(2021) Nawel Zaibi et al.   PLoS One

Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules

(2021) Jin Kyung Seok et al.   Frontiers in Immunology

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

(2021) Ji-Yeon Lee et al.   Diabetes & Metabolism Journal

Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework

(2020) Milton Packer   DIABETES OBESITY & METABOLISM

Innate immunity in diabetic kidney disease

(2020) Sydney C. W. Tang et al.   Nature Reviews Nephrology

Methionine abrogates the renoprotective effect of a low-protein diet against diabetic kidney disease in obese rats with type 2 diabetes

(2020) Munehiro Kitada et al.   Aging-US

Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance

(2020) Milton Packer   CIRCULATION

Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors

(2020) Milton Packer   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

(2020) So Ra Kim et al.   Nature Communications

Geniposide alleviates diabetic nephropathy of mice through AMPK/SIRT1/NF-κB pathway

(2020) Fengtao Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Empagliflozin alleviated mitochondrial fission via decreasing PGAM5.

(2020) Xiangyang Liu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation

(2020) Chintan N. Koyani et al.   PHARMACOLOGICAL RESEARCH

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion

(2020) Sergiy Sukhanov et al.   CELLULAR SIGNALLING

Proximal Tubule Autophagy Differs in Type 1 and 2 Diabetes

(2019) Shinsuke Sakai et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease

(2019) Keiichiro Matoba et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus

(2019) Weiling Leng et al.   Annals of Translational Medicine

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure

(2019) Deepak L. Bhatt et al.   Cell Metabolism

Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy

(2019) Ryoichi Bessho et al.   Scientific Reports

Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs

(2019) Rong Hu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition

(2019) Nitin A. Das et al.   CELLULAR SIGNALLING

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

(2018) Chenke Xu et al.   BIOCHEMICAL PHARMACOLOGY

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats

(2018) Krit Jaikumkao et al.   DIABETES OBESITY & METABOLISM

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity

(2018) Munehiro Kitada et al.   Nutrition & Metabolism

AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging

(2018) Mario D. Cordero et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway

(2018) Di Yao et al.   Molecular Medicine Reports

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy

(2017) Xiaoxin X. Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance

(2017) Daniel Garcia et al.   MOLECULAR CELL

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

(2016) Simon A. Hawley et al.   DIABETES

A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity

(2016) Munehiro Kitada et al.   DIABETOLOGIA

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice

(2016) Weiling Leng et al.   MEDIATORS OF INFLAMMATION

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

(2016) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

The NLRP3 inflammasome in kidney disease and autoimmunity

(2016) Holly L Hutton et al.   NEPHROLOGY

Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy

(2016) Yuan-ye Qiu et al.   PHARMACOLOGICAL RESEARCH

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

(2016) Michael A Weber et al.   Lancet Diabetes & Endocrinology

Diabetic Kidney Disease: A Report From an ADA Consensus Conference

(2014) Katherine R. Tuttle et al.   DIABETES CARE

Role of NF-κB in the pathogenesis of diabetes and its associated complications

(2014) Sandip Patel et al.   Pharmacological Reports

Metabolism of inflammation limited by AMPK and pseudo-starvation

(2013) Luke A. J. O'Neill et al.   NATURE

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?

(2013) Usha Panchapakesan et al.   PLoS One

Involvement of Endoplasmic Reticulum Stress in Albuminuria Induced Inflammasome Activation in Renal Proximal Tubular Cells

(2013) Li Fang et al.   PLoS One

SIRT1 inactivation induces inflammation through the dysregulation of autophagy in human THP-1 cells

(2012) Ai Takeda-Watanabe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

TLR-induced NF-κB activation regulates NLRP3 expression in murine macrophages

(2012) Yu Qiao et al.   FEBS LETTERS

The pathogenic role of the renal proximal tubular cell in diabetic nephropathy

(2012) S. C. W. Tang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Autophagy: Renovation of Cells and Tissues

(2011) Noboru Mizushima et al.   CELL

Structure of mammalian AMPK and its regulation by ADP

(2011) Bing Xiao et al.   NATURE

The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease

(2009) W. Lieberthal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE